



PATENT
082181-36154 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of:	:	
Tchistiakova et al.	:	Art Unit : 1649
	:	
Serial No. :	:	10/784,589
	:	
Filed :	:	February 23, 2004
	:	
Title :	:	LIGAND FOR VASCULAR
	:	ENDOTHELIAL GROWTH FACTOR
	:	RECEPTOR

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Terminal Disclaimer

Supratek Pharma Inc., a corporation of Quebec, Canada having a principal place of business at 455 Fenelon Boulevard, Suite 104, Dorval, Quebec, Canada H9S 5T8, is the assignee of the entire right, title and interest in and to the invention described and claimed in the application which matured into Letters Patent of the United States, U.S. Patent Number 6,733,755, issued May 11, 2004 and any and all continuation applications of said application which matured into said United States Letters Patent by virtue of an assignment by all of the inventors of said application which matured into Letters Patent of the United States, U.S. Patent Number 6,733,755, which assignment is recorded in the United States Patent and Trademark Office on May 18, 2001 at Reel 011819, Frame 0728.

The captioned application was filed as a continuation application of said application which matured into Letters Patent of the United States, U.S. Patent Number 6,733,755 and therefore by virtue of said assignment recorded in the United States Patent and Trademark Office on May 18, 2001 at Reel 011819, Frame 0728, is assigned to Supratek Pharma Inc.

03/22/2006 MBELETE1 00000037 033839 10784589
01 FC:2814 65.00 DA

#1067890 v1
082181-36154

Supratek Pharma Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the captioned application which would extend beyond the expiration date, including any extension obtained under 35 U.S.C. 156, of U.S. Patent Number 6,733,755 issued May 11, 2004.

Supratek Pharma Inc. further agrees that any patent so granted on the captioned application, together with any right to recover for its violation, shall be enforceable only for and during such period that the legal title to any patent granted on the captioned application shall be the same as the legal title to U.S. Patent Number 6,733,755 issued May 11, 2004. This agreement to run with any patent granted on the captioned application and to be binding upon the grantee, its successors or assigns.

Supratek Pharma Inc. does not disclaim the terminal part of the term of any patent granted on the captioned application prior to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of U.S. Patent Number 6,733,755 issued May 11, 2004, in the event that said patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is stautorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its fully statutory term as presently shortened by any terminal disclaimer.

Supratek Pharma Inc. makes the above disclaimer without prejudice to its right to extend, under 35 U.S.C. 154-156, the term of any U.S. patent granted on the captioned application beyond the term provided by this Terminal Disclaimer.


The undersigned is an attorney of record in the captioned application and has authority to sign on behalf of Supratek Pharma Inc.

The statutory fee of sixty-five dollars (\$65.00) is being charged to Deposit Account Number 03-3839 as per the document submitted herewith in duplicate. The

Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayments to Deposit Account Number 03-3839.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed at Newark, State of New Jersey, this 15th day of March, 2006.

By: 
William H. Epstein
Attorney for Applicants
Registration No. 20,008

Gibbons, Del Deo, Dolan,
Griffinger & Vecchione
One Riverfront Plaza
Newark, New Jersey 07102